January 18, 2017: Eli Lilly announced that it is acquiring CoLucid Pharma for $46.50 per share, or about $960M. CoLucid is focused on developing pain medications. Its lead product is an oral 5-HT1F agonist (lasmiditan) to treat migraine.
January 18, 2017: Merrimack has a new CEO. Richard Peters, the head of global rare diseases at Sanofi, will take over the company on Feb. 6. Merrimack’s former CEO Robert Mulroy stepped down in October.
January 18, 2017: Pfizer's CEO, Ian Read, recently spoke at the World Economic Forum in Davos, Switzerland. As part of his chat, Read discussed President-elect Donald Trump’s recent statements about drug pricing.
January 18, 2017: Struggling Theranos has made one more leadership change as it attempts to pivot from a clinical labs company to a health-tech development company.